Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Biotechnology

Healthcare
$37.75 -0.55%

-$0.29 today

Market cap
$3.71B
Beta
0.63
P/E (TTM)
-12.1
EPS (TTM)
-$4.39
52W Low $30.00High $63.95

Volume 1.30M

Average 1.16M

XENE Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Xenon Pharmaceuticals Inc.NASDAQ: XENE

Operating Margin · Q3 FY2026 · quarter ended Sep 2026

Operating margin not reported for Q3 FY2026

Over 3 fiscal years it narrowed by 3605.4 pp.

What to watch

Whether operating margin reaches the consensus estimate from 7 analysts of -25398.7% for the fiscal year ending Dec 2026, down from -4974.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearDec 2025
-4974.3%— YoY
LTMSep 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year—-20424.4 pp—
3 years-3605.4 pp+4851.0 pp+8456.4 pp
5 years+5004.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-4974.3%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How XENE compares with its peers on the latest reported figures

  • XENE's FY2025 operating margin of -4974.3% is the 7th highest of the 8 companies compared; the peer median is -13.5%.
  • Over three fiscal years its change of -3605.4 pp compares with a peer median of +7.0 pp.
XENE Competitors Peer median
Operating Margin for XENE and competitors
Company Period LTM level YoY 3-year change
NBIXNeurocrine Biosciences, Inc.LTM Sep 202623.8% +3.3 pp+4.9 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202620.3% +32.2 pp+7.0 pp
ACADACADIA Pharmaceuticals Inc.LTM Sep 202610.2% -12.8 pp+53.0 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-13.5% -23.1 pp-12.0 pp
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-24.3% +22.0 pp+332.8 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-611.0% ——
XENEXenon Pharmaceuticals Inc.FY2025-4974.3% —-3605.4 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-15058.2% ——
PRAXPraxis Precision Medicines, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding XENE) -13.5%+3.3 pp+7.0 pp

Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.44M9.43M007.5M
Cost of Revenue00167.51M2.56M2.54M
Gross Profit18.44M9.43M(167.51M)(2.56M)4.96M
Gross Margin100.0%100.0%——66.1%
Research & Development75.46M105.77M167.51M210.39M300.94M
Selling, General & Admin21.97M32.81M46.54M68.9M79.63M
Operating Expenses97.43M138.58M46.54M276.74M378.03M
Depreciation & Amortization906K1.41M3.54M2.56M2.54M
EBITDA(78.09M)(127.74M)(210.51M)(235.86M)(342.35M)
EBITDA Margin-423.5%-1354.0%——-4564.7%
Operating Income(78.99M)(129.14M)(214.05M)(279.3M)(373.07M)
Operating Margin-428.4%-1368.9%——-4974.3%
Interest Income466K8.71M27.62M41.94M26.83M
Interest Expense00000
Other Income / Expenses105K3.89M31.37M40.88M28.18M
Income Before Tax(78.89M)(125.26M)(182.69M)(238.42M)(344.89M)
Pre-Tax Margin-427.9%-1327.7%——-4598.6%
Income Tax Expense(6K)118K(292K)(4.09M)1.02M
Net Income(78.88M)(125.37M)(182.39M)(234.33M)(345.91M)
Net Margin-427.8%-1328.9%——-4612.1%
EPS (Basic)(1.77)(2.06)(2.73)(3.01)(4.36)
EPS (Diluted)(1.77)(2.06)(2.73)(3.01)(4.36)
Weighted Avg Shares43.63M60.54M66.89M77.89M79.25M
Weighted Avg Shares (Diluted)43.63M60.54M66.89M77.89M79.25M

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Intrinsic Alpha fair value

Locked

Current Price

$37.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.